UCB to acquire maker of antibody treatments for autoimmune diseases

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The U.S. is starting to feel the downstream effects of tighter immigration policies, as visa delays and uncertainty push international scientists away. Also, new funding for gene therapy startup Latus Bio, China’s tightening the reins on its supply chain, and more.Read the rest…